{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:09:40Z","timestamp":1789758580511,"version":"4.0.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Histopathological examination using hematoxylin and eosin (H&amp;E)-stained tissue is sufficient for diagnosing most melanocytic neoplasms as benign or malignant; however, diagnostic tools such as PRAME (preferentially expressed antigen in melanoma) immunohistochemistry (IHC) and the 23-gene expression profile (23-GEP) test can aid in the analysis of histopathologically ambiguous lesions, which can be referred to as diagnostically challenging, equivocal, indeterminate, or uncertain. When compared with the gold standard of H&amp;E diagnosis by a dermatopathologist, PRAME IHC showed 83.2% sensitivity and 99.3% specificity in an initial validation cohort and 23-GEP showed 91.5% sensitivity and 92.7% specificity in an independent validation cohort. In addition, 23-GEP has been evaluated in 3 studies with patients with known outcomes (eg, metastasis) and has reported metrics of 90.4%\u201396.3% sensitivity and 87.3%\u201396.2% specificity in distinguishing benign versus malignant melanocytic neoplasms. In this study, we present the utility of the 23-GEP test within 8 equivocal cases with various PRAME IHC staining patterns. Cases underwent histopathological review and received at least 4 and up to 5 diagnoses each. In samples where PRAME IHC is inconclusive, conflicting, or ambiguous regarding a final diagnosis, the 23-GEP can provide additional diagnostic information to upgrade or downgrade the overall malignant potential of the lesion in question.<\/jats:p>","DOI":"10.1097\/dad.0000000000003365","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:00:40Z","timestamp":1782457240000},"page":"791-797","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Demonstration of 23-Gene Expression Profile Test Utility Within PRAME Immunohistochemistry Results: A Case Series"],"prefix":"10.1097","volume":"48","author":[{"given":"Gregory A.","family":"Hosler","sequence":"first","affiliation":[{"name":"ProPath, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Castle Biosciences, Inc., Friendswood, TX;"},{"name":"Icahn School of Medicine at Mount Sinai, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-0285","authenticated-orcid":false,"given":"Etan","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Dermatopathology, Kansas City University-Graduate Medical Education Consortium, Oviedo, FL; and"},{"name":"Advanced Dermatology and Cosmetic Surgery, Oviedo, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"R1-20260918","doi-asserted-by":"crossref","first-page":"j2813","DOI":"10.1136\/bmj.j2813","article-title":"Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study","volume":"357","author":"Elmore","year":"2017","journal-title":"BMJ"},{"key":"R2-20260918","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/cup.13648","article-title":"Immunohistochemistry utilization in the diagnosis of melanoma","volume":"47","author":"Dinehart","year":"2020","journal-title":"J Cutan Pathol"},{"key":"R3-20260918","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jamadermatol.2023.6417","article-title":"Immunohistochemistry for diagnosing melanoma in older adults","volume":"160","author":"Ojukwu","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R4-20260918","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R5-20260918","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000002440","article-title":"Immunohistochemistry for PRAME in dermatopathology","volume":"45","author":"Lezcano","year":"2023","journal-title":"Am J Dermatopathol"},{"key":"R6-20260918","doi-asserted-by":"crossref","first-page":"154915","DOI":"10.1016\/j.prp.2023.154915","article-title":"PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases","volume":"251","author":"Lo Bello","year":"2023","journal-title":"Pathol - Res Pract"},{"key":"R7-20260918","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/cancers13153864","article-title":"Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas","volume":"13","author":"Gassenmaier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R8-20260918","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/cup.14286","article-title":"PRAME expression is similar in scar and desmoplastic melanoma","volume":"49","author":"Plotzke","year":"2022","journal-title":"J Cutan Pathol"},{"key":"R9-20260918","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/his.14904","article-title":"Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions","volume":"83","author":"Kunc","year":"2023","journal-title":"Histopathology"},{"key":"R10-20260918","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Cutaneous Melanoma V.2.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf","author":"Swetter","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"R11-20260918","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R13-20260918","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cup.14135","article-title":"Appropriate use criteria for ancillary diagnostic testing in dermatopathology: new recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee","volume":"49","author":"Fung","year":"2022","journal-title":"J Cutan Pathol"},{"key":"R14-20260918","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma","volume":"42","author":"Clarke","year":"2015","journal-title":"J Cutan Pathol"},{"key":"R15-20260918","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cncr.30385","article-title":"An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi","volume":"123","author":"Clarke","year":"2017","journal-title":"Cancer"},{"key":"R16-20260918","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-16-0958","article-title":"Diagnostic distinction of malignant melanoma and benign Nevi by a gene expression signature and correlation to clinical outcomes","volume":"26","author":"Ko","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R17-20260918","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.humpath.2018.12.001","article-title":"Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions","volume":"86","author":"Ko","year":"2019","journal-title":"Hum Pathol"},{"key":"R18-20260918","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pme-2020-0048","article-title":"Clinical validity of a gene expression signature in diagnostically uncertain neoplasms","volume":"17","author":"Clarke","year":"2020","journal-title":"Personalized Med"},{"key":"R19-20260918","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/DAD.0000000000002808","article-title":"Appropriate statistical methods to assess cross-study diagnostic 23-Gene expression profile test performance for cutaneous melanocytic neoplasms","volume":"46","author":"Goldberg","year":"2024","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"R20-20260918","first-page":"596","article-title":"Evaluating the Diagnostic Concordance of MyPath Melanoma Assay and PRAME Immunohistochemistry in Challenging Melanocytic Lesions","volume":"47","author":"Regmi","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"R21-20260918","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/modpathol.2016.84","article-title":"Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions","volume":"29","author":"Minca","year":"2016","journal-title":"Mod Pathol"},{"key":"R22-20260918","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/bmm.15.11","article-title":"Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions","volume":"9","author":"Warf","year":"2015","journal-title":"Biomarkers Med"},{"key":"R23-20260918","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2023.05.002","article-title":"Ancillary testing for melanoma: current trends and practical considerations","volume":"140","author":"Hosler","year":"2023","journal-title":"Hum Pathol"},{"key":"R24-20260918","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/00313020412331283905","article-title":"The approach to the patient with a difficult melanocytic lesion","volume":"36","author":"Elder","year":"2004","journal-title":"Pathology"},{"key":"R25-20260918","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/cup.14635","article-title":"Diagnostic discordance among histopathological reviewers of melanocytic lesions","volume":"51","author":"Hosler","year":"2024","journal-title":"J Cutan Pathol"},{"key":"R26-20260918","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"R27-20260918","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/cup.14495","article-title":"PRAME expression in cutaneous melanoma does not correlate with disease-specific survival","volume":"50","author":"Parra","year":"2023","journal-title":"J Cutan Pathol"},{"key":"R28-20260918","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.04.1965","article-title":"Clinical utility of 23-gene expression profiling and concordance with PRAME immunohistochemistry in melanocytic neoplasms: a retrospective diagnostic accuracy study","author":"Jaeger","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"R29-20260918","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:00:31Z","timestamp":1789758031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003365","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}